Get the Stockscreener App
7.15
8.80%
-0.69
After Hours:
6.83
-0.32
-4.48%
Cns Pharmaceuticals Inc stock is traded at $7.15, with a volume of 1.49M.
It is down -8.80% in the last 24 hours and up +216.37% over the past month.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
See More
Previous Close:
$7.84
Open:
$5.71
24h Volume:
1.49M
Relative Volume:
1.14
Market Cap:
$5.80M
Revenue:
-
Net Income/Loss:
$-15.85M
P/E Ratio:
-0.2991
EPS:
-23.9055
Net Cash Flow:
$-13.83M
1W Performance:
+215.72%
1M Performance:
+216.37%
6M Performance:
+4.81%
1Y Performance:
-45.83%
1-Day Range:
$5.27
$7.30
1-Week Range:
$2.21
$10.54
52-Week Range:
$1.90
$34.80
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
7.15 | 6.36M | 0 | -15.85M | -13.83M | -23.91 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Why did CNSP stock surge 330% today? - MSN
CNS Pharma sees 250% spike from oversubscribed private placement - Mugglehead Investment Magazine
CNS Pharmaceuticals (CNSP) Stock Skyrockets 215% on $22.5M Funding Round - MEXC
Why CNS Pharmaceuticals (CNSP) Stock Is Up 215% Today - MEXC
CNSP Secures $22.5 Million in Private Placement Financing - GuruFocus
CNS Pharmaceuticals (CNSP) Stock Skyrockets 215% on $22.5M Fundraise - MEXC
CNS Pharmaceuticals Raises $22.5 Million in Private Placement to Fuel Asset Acquisition - MEXC
CNS Pharmaceuticals (NASDAQ: CNSP) Secures $22.5M Private Placement Financing - The Globe and Mail
Gold Falls Over 2%; US Factory Orders Rise In March - Benzinga
CNS Pharmaceuticals Announces Private Placement Agreement and Pre-Funded Warrants Offering – Details and Legal Terms - Minichart
Why is CNS Pharmaceuticals stock up 250% today? By Investing.com - Investing.com Nigeria
Nano-cap CNS Pharmaceuticals stock explodes as capital raise fuels pivot - MSN
Why is CNS Pharmaceuticals stock up 250% today? - Investing.com
CNS Pharmaceuticals raises $22.5 million in private placement By Investing.com - Investing.com South Africa
Trending Stocks Today | CNS Pharmaceuticals Soars 280.77% - Moomoo
CNSP Stock Explodes Higher As Traders Hunt Volatility - StocksToTrade
Why Is CNS Pharmaceuticals Stock (CNSP) Up Today? - TipRanks
Why Did CNSP Stock Surge 330% Today? - Stocktwits
Dow Falls Over 150 Points; Tyson Foods Posts Upbeat Earnings - Benzinga
Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot - Benzinga
CNSP Stock Volatility Spikes As Traders Watch Key Levels - timothysykes.com
CNS Pharmaceuticals prices 650,000 shares at $2.30 in private placement - TipRanks
CNS Pharmaceuticals raises $22.5 million in private placement - Investing.com
CNS Pharmaceuticals Announces Private Placement and Board Changes - TipRanks
CNS Pharmaceuticals Raises $22.5 Million in Private Placement; Signs Registration and Placement Deals - TradingView
CNS Pharmaceuticals (NASDAQ: CNSP) completes $22.5M private placement and board change - Stock Titan
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing - ACCESS Newswire
Biotech CNS raises $22.5M to buy clinical-stage drug assets - Stock Titan
CNS Pharmaceuticals, Inc. 2025 Annual Report: Executive Compensation, Governance, and Audit Details - Minichart
CNS Pharmaceuticals (NASDAQ: CNSP) details CEO transition, pay and ownership in 10-K/A - Stock Titan
CNS Pharmaceuticals Inc. (CNSP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CNS Pharmaceuticals Inc. (CNSP) shares fall 3.27% after posting a far wider than expected Q4 2025 per-share loss. - Cổng thông tin điện tử Tỉnh Sơn La
CNS Pharma (CNSP) Stock: Is It Showing Downtrend Signals | Q4 2025: Profit Disappoints - Cổng thông tin điện tử Tỉnh Sơn La
Is CNS Pharma (CNSP) stock showing technical strength (Smart Money Outflows) 2026-04-18Trader Community Insights - Xã Vĩnh Công
Ikarian group holds 5.7% of CNS Pharmaceuticals (NASDAQ: CNSP) - Stock Titan
AtaiBeckley (ATAI) Reports Phase 2a Data in CNS Drugs - Yahoo Finance
Gains Report: Is CNS Pharmaceuticals Inc being accumulated by smart money2026 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Is CNS Pharma (CNSP) Stock Underperforming | CNSP Q4 Earnings: Misses Estimates by $4.96Market Hype Signals - Cổng thông tin điện tử tỉnh Lào Cai
Profit Recap: Why is CNS Pharmaceuticals Inc stock going down2026 Macro Impact & Smart Swing Trading Alerts - baoquankhu1.vn
Exit Recap: Is CNS Pharmaceuticals Inc in a long term uptrend2026 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn
CNS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
CNSP PE Ratio & Valuation, Is CNSP Overvalued - Intellectia AI
CNS Pharmaceuticals | 10-K: Annual report - Moomoo
CNS Pharmaceuticals 10-K: Net loss $15.85M, Loss per share $35.75 - TradingView — Track All Markets
CNS Pharmaceuticals (NASDAQ: CNSP) pivots to neurology and oncology amid going concern risk - Stock Titan
Pharma News: Will CNS Pharmaceuticals Inc outperform small cap indexesDip Buying & Verified Short-Term Trading Plans - baoquankhu1.vn
CNS Pharmaceuticals Inc expected to post a loss of $5.09 a shareEarnings Preview - TradingView
Lunai Bioworks, Inc. (LNAI) Stock: No-Reset Convertible Deal Boosts CNS Drug Development Edge - parameter.io
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications - PR Newswire
Is CNS Pharmaceuticals Inc in a long term uptrend2026 Earnings & Real-Time Market Sentiment Reports - baoquankhu1.vn
Stop Loss: Will CNS Pharmaceuticals Inc outperform small cap indexesPortfolio Performance Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):